Key result
DOAC use was associated with a decreased risk of stroke and death compared with warfarin among patients with incident nonvalvular atrial fibrillation (HR 0.90; 95% CI 0.83-0.97).
Why the study?
Do direct oral anticoagulants (DOACs) reduce the composite of stroke and death compared to warfarin in patients with incident nonvalvular atrial fibrillation?
Cohort (n=34,965)
Do direct oral anticoagulants (DOACs) reduce the composite of stroke and death compared to warfarin in patients with incident nonvalvular atrial fibrillation?
Hazard Ratio: 0.9 (95% CI 0.83–0.97)
In a real-world Canadian cohort, DOACs were associated with a lower risk of stroke and death compared to warfarin in patients with incident nonvalvular atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Should not yet change practice in nonvalvular AF; extends observational data but leaves superiority open pending RCTs.
Yu et al. (2017) conducted a cohort in Incident nonvalvular atrial fibrillation (n=34,965). Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Composite of stroke and death (HR 0.90, 95% CI 0.83-0.97). DOAC use was associated with a decreased risk of stroke and death compared with warfarin among patients with incident nonvalvular atrial fibrillation (HR 0.90; 95% CI 0.83-0.97).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: